BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Decreases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 12.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,397 shares of the medical research company’s stock after selling 4,463 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in IQVIA were worth $7,203,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in IQVIA in the third quarter worth about $147,683,000. 1832 Asset Management L.P. grew its stake in shares of IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after purchasing an additional 376,595 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of IQVIA during the 2nd quarter valued at about $70,610,000. Finally, Impax Asset Management Group plc lifted its stake in shares of IQVIA by 19.3% in the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after purchasing an additional 264,555 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

NYSE:IQV opened at $200.84 on Monday. The company has a market capitalization of $36.45 billion, a P/E ratio of 26.36, a P/E/G ratio of 2.07 and a beta of 1.51. The business’s 50-day moving average is $218.67 and its 200 day moving average is $226.11. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73.

Analyst Upgrades and Downgrades

A number of analysts have commented on IQV shares. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Truist Financial decreased their target price on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Barclays cut their price target on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Morgan Stanley decreased their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Finally, StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.